title: Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit.
abstract: BACKGROUND
  Predictors of outcome and rates of successful discharge have not been defined for patients with acute leukemia admitted to intensive care units (ICUs) in the US.
  
  
  METHODS
  This is a retrospective analysis of 90 patients with acute leukemia (no history of bone marrow transplant) admitted to an ICU from 2001-2004. The primary endpoints were improvement and subsequent discharge from the ICU, discharge from the hospital, and 2-month survival after hospital discharge. Secondary endpoints were 6- and 12-month survival. Univariate and multivariate logistic regression analyses were performed to identify factors predicting outcome.
  
  
  RESULTS
  The median age of patients was 54 years and 48 (53%) were male. The most common reason for ICU transfer for all patients was respiratory compromise. The majority of all patients (68%) were eventually placed on ventilator support and approximately half required pressors. During the ICU course, 29 patients (32%) improved and subsequently resumed aggressive leukemia management, and 24 patients (27%) survived to be discharged from the hospital. The 2-, 6-, and 12-month overall survival was 24 (27%), 16 (18%), and 14 (16%), respectively. Higher APACHE II score, use of pressors, undergoing bone marrow transplantation preparative regimen, and adverse cytogenetics predicted worse outcome. Newly diagnosed leukemia, type of leukemia, or age did not.
  
  
  CONCLUSIONS
  One of 4 patients with acute leukemia survived an ICU admission to be discharged from the hospital and were alive 2 months later. A diagnosis of acute leukemia should not disqualify patients from an ICU admission.
authors.affiliation: Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA.
authors.forename: Snehal G
authors.initials: SG
authors.lastname: Thakkar
authors.forename: Alex Z
authors.initials: AZ
authors.lastname: Fu
authors.forename: John W
authors.initials: JW
authors.lastname: Sweetenham
authors.forename: Zachariah A
authors.initials: ZA
authors.lastname: Mciver
authors.forename: Sanjay R
authors.initials: SR
authors.lastname: Mohan
authors.forename: Giridharan
authors.initials: G
authors.lastname: Ramsingh
authors.forename: Anjali S
authors.initials: AS
authors.lastname: Advani
authors.forename: Ronald
authors.initials: R
authors.lastname: Sobecks
authors.forename: Lisa
authors.initials: L
authors.lastname: Rybicki
authors.forename: Matt
authors.initials: M
authors.lastname: Kalaycio
authors.forename: Mikkael A
authors.initials: MA
authors.lastname: Sekeres
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016026:Bone Marrow Transplantation; D005260:Female; D017052:Hospital Mortality; D006760:Hospitalization; D006801:Humans; D007362:Intensive Care Units; D007902:Length of Stay; D015470:Leukemia, Myeloid, Acute / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality* / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome